On October 8, METIS TECHBIO-P fell 5.04% in regular trading, trading at HK$16.06/share, with Turnover of HK$52.4512 million. The stock extended its decline from the previous session, reflecting sustained weakness across the biotechnology complex.

The broader biotechnology sector traded lower, with peer stocks showing mixed but mostly negative performance. AKESO edged up 0.27%, BEONE MEDICINES rose 0.18%, while INNOVENT BIO fell 0.72%, CANSINOBIO declined 0.58%, and 3SBIO slipped 0.13%. The sector-wide pullback follows a sharp rally the day prior, with market participants citing profit-taking and softer risk sentiment toward high-valuation AI-driven drug developers.

METIS TECHBIO-P is a China-based company primarily engaged in artificial intelligence-driven nanomaterial innovation. Its NanoForge platform underpins an AI-powered nanotech innovation system encompassing lipid libraries, foundation models, the METiS AI agent, quantum chemistry and molecular dynamics simulations, and AI-driven screening, enabling rational design, optimization, and validation of advanced nanomaterials and payloads.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)